<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="474">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364336</url>
  </required_header>
  <id_info>
    <org_study_id>150082</org_study_id>
    <secondary_id>15-DK-0082</secondary_id>
    <nct_id>NCT02364336</nct_id>
  </id_info>
  <brief_title>Mechanisms Associated With Favorable Responses to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B</brief_title>
  <official_title>Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Chronic hepatitis B is caused by a virus that infects the liver. Cure is not possible but
      the virus can be controlled with the use of antiviral medicines,. Researchers think that
      adding a second antiviral medicine might help.

      Objective:

      - To understand how peginterferon might help treat people with chronic hepatitis B. Also, to
      see if peginterferon is safe to use with other antiviral medications.

      Eligibility:

      - Adults age 18 and older who have chronic hepatitis B and had therapy with 1 or more oral
      medicines for hepatitis B for at least 4 years.

      Design:

        -  Participants will be screened with physical exam and medical history. They will
           complete health questionnaires about their levels of fatigue and pain. They will have
           blood and urine tests. They may have an eye exam.

        -  Participants also will have a Fibroscan. A test to measure how stiff your liver is.

        -  Eligible participants will have a liver biopsy. Blood will be drawn.

        -  Participants will be admitted to the NIH Clinical Center. They will be injected with
           the study drug. Then they will have a second liver biopsy. They will be discharged 24
           hours later.

        -  Participants will give themselves study drug injections under the skin weekly for 24
           weeks.

        -  Participants will have 5 clinic visits during the 24-week treatment period. Then they
           will have follow-up visits every 12 weeks for 48 weeks.

        -  During visits, participants may have a physical exam and medical history. They may have
           blood and urine tests. They may have a Fibroscan and complete questionnaires. At the
           final visit, they will also have a Fibroscan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B virus (HBV) infection is a leading cause of liver associated morbidity
      and mortality. Currently available first-line therapies for treatment of chronic hepatitis B
      include pegylated interferon-alpha and the nucleos(t)ide analogues (NUCs) entecavir and
      tenofovir. These were shown to effectively suppress viral replication, but their ability to
      induce durable off-treatment response is limited to a small subset of patients. Combination
      treatment with peginterferon and NUCs has been attempted in several randomized controlled
      trials, with no apparent advantage over either agent given alone. In these studies however,
      treatment with peginterferon was initiated either simultaneously or shortly after NUCs
      administration. The efficacy of peginterferon following long-term viral suppression with
      NUCs was only tested in one small pilot study, nevertheless showing 60% HBsAg loss rate.

      The underlying mechanisms responsible for improved efficacy of peginterferon in this setting
      are unknown and warrant further investigation. In this single arm study we propose to
      evaluate the efficacy and mechanisms associated with response to peginterferon add-on
      therapy following a minimum of 192 weeks of viral suppression induced by NUCs in a group of
      chronic HBV infected patients. Sixty patients with either HBeAg positive (n=30) or negative
      (n=30) chronic HBV infection will be enrolled to this study. After medical evaluation and
      pretreatment liver biopsy, treatment with subcutaneous injections of pegylated interferon
      alpha-2a 180 g per week will be given for a total of 24 weeks, followed by an off-treatment
      evaluation period of 48 weeks. A second liver biopsy will be performed six hours following
      the first peginterferon injection. Primary end-point for this study will be the change in
      interferon-stimulated-genes response before and after first interferon injection in
      responders versus non-responders to treatment. The responsiveness to IFN-based therapy of
      treatment responders vs nonresponders will additionally be evaluated by studying
      intrahepatic and peripheral blood natural killer cells. The study will also assess HBeAg and
      HBsAg loss and seroconversion rates in comparison to historical controls treated with either
      peginterferon or NUCs monotherapy. Finally, we will assess whether treatment responders
      develop an HBV-specific T cell response similar in quantity and quality to that of patients
      who spontaneously resolve HBV infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in interferon-stimulated-genes</measure>
    <time_frame>Week 4 of Therapy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBeAg and HBsAg seroconversion</measure>
    <time_frame>24 &amp; amp; 48 weeks off</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Inclusion criteria: HBeAg positive group

          1. Age &gt; 18 years and older, male or female.

          2. Known serum HBsAg and HBeAg positivity at the time of screening.

          3. Ongoing treatment with one or more NUCs for at least 192 weeks before study entry.
             Subjects may have a brief interruption of treatment for medical reasons (e.g. breast
             feeding) not to exceed 8 weeks and none within the 48 weeks before study entry.

          4. HBV DNA levels &lt; 100 IU/mL, measured at least 12 months prior to, and upon enrollment
             to the study.

          5. ALT level less than or equal to 2 ULN based on at least two determinations taken at
             least one month apart during the 24 weeks before study entry with the second being at
             time of screening

          6. Written informed consent

        Inclusion criteria: HBeAg negative group

          1. Age &gt; 18 years and older, male or female.

          2. Known serum HBsAg positivity and HBeAg negativity at the time of screening.

          3. Ongoing treatment with one or more NUCs for at least 192 weeks before study entry.
             Subjects may have a brief interruption of treatment for medical reasons (e.g. breast
             feeding) not to exceed 8 weeks and none within the 48 weeks before study entry.

          4. HBV DNA levels &lt; 100 IU/mL, measured at least 12 months prior to, and upon enrollment
             to the study

          5. ALT level less than or equal to 2 ULN based on at least two determinations taken at
             least one month apart during the 24 weeks before study entry with the second being at
             time of screening

          6. Written informed consent

        EXCLUSION CRITERIA:

        Exclusion criteria (for both eAg positive and negative patients)

          1. Co-infection with HDV as defined by the presence of anti-HDV in serum and/or HDV
             antigen in the liver.

          2. Co-infection with HCV as defined by the presence of HCV RNA in serum.

          3. Co-infection with HIV as defined by the presence of anti-HIV in serum.

          4. Decompensated liver disease as defined by serum bilirubin &gt; 2.5 mg/dL (with direct
             bilirubin &gt; 0.5 mg/dL), prothrombin time of greater than 2 seconds prolonged, a serum
             albumin of less than 3 g/dL, or a history of ascites, variceal bleeding or hepatic
             encephalopathy.

          5. Presence of other causes of liver disease, (i.e. hemochromatosis, Wilson disease,
             alcoholic liver disease, severe nonalcoholic steatohepatitis defined as the presence
             of marked ballooning injury on liver biopsy, alpha-1-anti-trypsin deficiency).

          6. A history of organ transplantation or in the absence of organ transplantation, any
             immunosuppressive therapy requiring the use of more than 5 mg of prednisone (or its
             equivalent) daily.

          7. Significant systemic illness other than liver diseases including congestive heart
             failure, renal failure, chronic pancreatitis and diabetes mellitus with poor control,
             that in the opinion of the investigator may interfere with therapy.

          8. Pregnancy or inability to practice contraception in patients capable of bearing or
             fathering children

          9. Lactating women.

         10. Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the
             liver that is suggestive of HCC, or an alpha-fetoprotein level of greater than 500
             ng/mL.

         11. eGFR &lt; 50 ml/min, serum creatinine &gt; 1.3 mg/dl or urine protein &gt; 1 gram/24-hours

         12. History of hypersensitivity to pegylated interferon-alpha

         13. Platelet count &lt; 70 mm(3)/dL

         14. Hgb &lt; 12 g/dL for males and &lt; 11 g/dL for females

         15. Active ethanol/drug abuse/psychiatric problems such as major depression,
             schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or
             personality disorder that, in the investigator s opinion, might interfere with
             participation in the study.

         16. History of malignancy or treatment for a malignancy within the past 3 years (except
             adequately treated carcinoma in situ or basal cell carcinoma of the skin).

         17. Any medical condition requiring, or likely to require, chronic systemic
             administration of corticosteroids or other immunosuppressive medications during the
             course of this study.

         18. History of immune-mediated disease, or cerebrovascular, chronic pulmonary or cardiac
             disease associated with functional limitation, retinopathy, uncontrolled thyroid
             disease, poorly controlled diabetes or uncontrolled seizure disorder, as determined
             by a study physician.

         19. Presence of conditions that, in the opinion of the investigators, would not allow the
             patient to be followed in the current study for at 1 year.

         20. For subjects who interrupt therapy, documentation of a viral load &gt; 1,000 IU/ml while
             off therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc G Ghany, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Fryzek</last_name>
    <phone>(301) 435-6122</phone>
    <email>nancy.fryzek@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc G Ghany, M.D.</last_name>
    <phone>(301) 402-5115</phone>
    <email>mg228m@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@mail.cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2015-DK-0082.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008 Jul;8(7):559-68. doi: 10.1038/nri2314. Review.</citation>
    <PMID>18575461</PMID>
  </reference>
  <reference>
    <citation>Ouzan D, PÃ©naranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013 Dec;58(4):713-7. doi: 10.1016/j.jcv.2013.09.020. Epub 2013 Sep 29.</citation>
    <PMID>24183313</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>October 28, 2015</lastchanged_date>
  <firstreceived_date>February 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
